About the compound
Co-formulated lyophilized vial of BPC-157, TB-500, and MGF (IGF-1Ec C-terminal E-domain 24-mer).
Lyophilized blend of BPC-157, TB-500, and MGF (24-residue C-terminal E-domain peptide of the IGF-1Ec splice variant). All three components are co-formulated in a single vial at the masses indicated on the variant label.
Reconstitution. For in-vitro laboratory handling, dissolve with bacteriostatic water (0.9% benzyl alcohol). Compound is hygroscopic — handle in low-humidity conditions and re-cap immediately.
Stability profile. Lyophilized: stable at room temperature for up to 30 days sealed; long-term storage at -20 °C recommended. Reconstituted material: stable at 2–8 °C for up to 14 days.
Selected primary literature.
- Sikiric P et al., 1993, J Physiol Paris 87:313 — original BPC-157 sequence characterization.
- Goldstein AL et al., 2005, Expert Opin Biol Ther 5(11):1505 — review of thymosin β-4 structural biology.
What remains uncharacterized: per-component concentration-response in any specific in-vitro model system is not implied here. Components are individually characterized in the structural-class literature cited above.
For research use only. Not for human or animal consumption.


